HIV Prevention Drug Lenacapavir Could Cut Cases, But USAID Cuts 2026

HIV prevention drug lenacapavir could dramatically reduce new infections worldwide, yet USAID cuts are preventing access for those most in need, according to experts at the Aids 2026 Conference in Rio de Janeiro. This injectable PrEP requires only two doses per year, offering a breakthrough for vulnerable populations. However, the dissolution of USAID has slashed 73% of donor-funded HIV prevention resources, leaving millions at risk.

Why Lenacapavir Is a Game-Changer in HIV Prevention

Lenacapavir, an injectable HIV prevention medication, is 99% effective in preventing sexually transmitted HIV when taken consistently. Unlike daily oral PrEP pills or bimonthly injections, lenacapavir requires just two injections annually. This makes it ideal for individuals facing poverty, stigma, or living in remote areas with limited healthcare access.

The World Health Organization (WHO) recommended in 2025 that governments prioritize scaling up lenacapavir availability. A mathematical model by WHO and the United Nations estimates that widespread use could prevent 41% of new HIV infections in South Africa, Zimbabwe, and western Kenya.

How Lenacapavir Compares to Current PrEP Options

Impact of USAID Cuts on Global HIV Prevention

USAID historically provided 73% of donor-funded resources for HIV prevention globally, according to a study in the Lancet Global Health. As of July 2026, the Trump administration has dissolved USAID, leading to a dramatic decline in HIV prevention investment. This has halted distribution of lenacapavir and other PrEP medications in low-income countries.

Experts warn that without funding, the 41% infection reduction projected by modeling will not materialize. The most affected regions include sub-Saharan Africa, where HIV prevalence is highest and healthcare infrastructure is weakest.

Key Takeaways for Policymakers and Advocates

• Lenacapavir offers a twice-yearly injection that could overcome adherence and access barriers.
• WHO recommends global investment in lenacapavir, but USAID cuts have reduced donor funding by 73%.
• Mathematical modeling shows a potential 41% reduction in new HIV cases in high-burden areas.
• Immediate action is needed to restore funding and ensure equitable access to HIV prevention.

What Can Be Done to Restore Access?

Alternative funding sources, such as the Global Fund and private philanthropy, are being explored, but they currently cannot replace USAID's contribution. Advocacy groups are calling for international cooperation and emergency funding to bridge the gap.

Healthcare providers in affected regions are reporting stockouts of PrEP medications, and new lenacapavir shipments have been cancelled. Without urgent intervention, the global goal of ending AIDS by 2030 is at risk.

FAQ

Best Products We’ve Tested and Rated

Our testing team has hands-on reviews of walking shoes supination, sumo deadlift shoes, work boots plantar fasciitis, cushioned running shoes, and womens running shoes it band syndrome. Every option below was compared across price, build quality, and real-world performance, with honest pros and cons. We update these guides regularly as new models arrive, so the recommendations stay current.

Our testing team has hands-on reviews of trampoline ski training, leg press hack squat combo, 4d massage chair, stall bars, and speed bag platform home. Every option below was compared across price, build quality, and real-world performance, with honest pros and cons. We update these guides regularly as new models arrive, so the recommendations stay current.